Patents by Inventor Veronique Damagnez

Veronique Damagnez has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Assays and reagents for identifying anti-fungal agents, and uses related thereto
    Publication number: 20020168748
    Abstract: The present invention relates to rapid, reliable and effective assays for screening and identifying pharmaceutically effective compounds that specifically inhibit the biological activity of fungal GTPase proteins, particularly GTPases involved in cell wall integrity, hyphael formation, and/or other cellular functions critical to pathogenesis.
    Type: Application
    Filed: August 31, 2001
    Publication date: November 14, 2002
    Inventors: Vivian Berlin, Veronique Damagnez, Susan E. Smith
  • Immunosuppressant target proteins
    Patent number: 6464974
    Abstract: The present invention relates to the discovery of novel proteins of mammalian origin which are immediate downstream targets for FKBP/rapamycin complexes and provides, e.g., isolated polypeptides, nucleic acids encoding such, antibodies, screening methods, and diagnostic and therepeutic methods.
    Type: Grant
    Filed: January 23, 1998
    Date of Patent: October 15, 2002
    Assignee: Ariad Pharmaceuticals
    Inventors: Vivian Berlin, Maria Isabel Chiu, Guillaume Cottarel, Veronique Damagnez
  • Nucleic acids for identifying anti-fungal agents, and uses related thereto
    Patent number: 6455281
    Abstract: The present invention relates to rapid, reliable and effective assays for screening and identifying pharmaceutically effective compounds that specifically inhibit the biological activity of fungal GTPase proteins, particularly GTPases involved in cell wall integrity, hyphael formation, and/or other cellular functions critical to pathogenesis. Another aspect of the present invention relates to novel Candida genes and gene products.
    Type: Grant
    Filed: December 20, 1996
    Date of Patent: September 24, 2002
    Assignee: GPC Biotech Inc.
    Inventors: Vivian Berlin, Veronique Damagnez, Susan E. Smith
  • Assays and reagents for identifying anti-fungal agents, and uses related thereto
    Patent number: 6277564
    Abstract: The present invention relates to rapid, reliable and effective assays for screening and identifying pharmaceutically effective compounds that specifically inhibit the biological activity of fungal GTPase proteins, particularly GTPases involved in cell wall integrity, hyphael formation, and/or other cellular functions critical to pathogenesis. Another aspect of the present invention relates to novel Candida genes and gene products.
    Type: Grant
    Filed: April 23, 1997
    Date of Patent: August 21, 2001
    Assignee: GPC Biotech Inc.
    Inventors: Vivian Berlin, Veronique Damagnez, Susan E. Smith
  • Assays and reagents for identifying anti-fungal agents, and uses related thereto
    Patent number: 6271197
    Abstract: The present invention relates to rapid, reliable and effective assays for screening and identifying pharmaceutically effective compounds that specifically inhibit the biological activity of fungal GTPase proteins, particularly GTPases involved in cell wall integrity, hyphael formation, and/or other cellular functions critical to pathogenesis. Another aspect of the present invention relates to novel Candida genes and gene products.
    Type: Grant
    Filed: April 23, 1997
    Date of Patent: August 7, 2001
    Assignees: GPC-Biotech Inc., The Johns Hopkins University
    Inventors: Vivian Berlin, David E. Levin, Yoshikazu Ohya, Veronique Damagnez, Susan E. Smith
  • Assay and reagents for identifying anti-proliferative agents
    Patent number: 6251585
    Abstract: The present invention makes available assays and reagents for identifying anti-proliferative agents, such as mitotic and meiotic inhibitors. The present assay provides a simple and rapid screening test which relies on scoring for positive cellular proliferation as indicative of anti-mitotic or anti-meiotic activity, and comprises contacting a candidate agent with a cell which has an impaired cell-cycle checkpoint and measuring the level of proliferation in the presence and absence of the agent. The checkpoint impairment is such that it either causes premature progression of the cell through at least a portion of a cell-cycle or inhibition of normal progression of the cell through at least a portion of a cell-cycle, but can be off-set by the action of an agent which inhibits at least one regulatory protein of the cell-cycle in a manner which counter-balances the effect of the impairment.
    Type: Grant
    Filed: April 24, 1995
    Date of Patent: June 26, 2001
    Assignee: Mitotix, Inc.
    Inventors: Giulio Draetta, Guillaume Cottarel, Veronique Damagnez
  • Immunosuppressant target proteins
    Patent number: 6150137
    Abstract: The present invention relates to the discovery of novel proteins of mammalian origin which are immediate downstream targets for FKBP/rapamycin complexes.
    Type: Grant
    Filed: December 20, 1994
    Date of Patent: November 21, 2000
    Assignee: Ariad Pharmaceuticals, Inc.
    Inventors: Vivian Berlin, Maria Isabel Chiu, Guillaume Cottarel, Veronique Damagnez
  • Immunosuppressant target proteins
    Patent number: 6127521
    Abstract: The present invention relates to the discovery of novel proteins of mammalian origin which are immediate downstream targets for FKBP/rapamycin complexes.
    Type: Grant
    Filed: January 23, 1998
    Date of Patent: October 3, 2000
    Assignee: ARIAD Pharmaceuticals, Inc.
    Inventors: Vivian Berlin, Maria Isabel Chiu, Guillaume Cottarel, Veronique Damagnez
  • Ubiquitin conjugating enzymes
    Patent number: 6068982
    Abstract: The present invention relates to drug screening assays which provide a systematic and practical approach for the identification of candidate agents able to inhibit ubiquitin-mediated degradation of a cell-cycle regulatory protein, such as p53, p27, myc, fos, MAT.alpha.2, or cyclins. The invention further relates to novel ubiquitin-conjugating enzymes, and uses related thereto.
    Type: Grant
    Filed: December 17, 1996
    Date of Patent: May 30, 2000
    Assignee: Mitotix, Inc.
    Inventors: Mark Rolfe, Maria Isabel Chiu, Guillaume Cottarel, Vivian Berlin, Veronique Damagnez, Giulio Draetta
  • Ubiquitin conjugating enzymes
    Patent number: 5968761
    Abstract: The present invention relates to drug screening assays which provide a systematic and practical approach for the identification of candidate agents able to inhibit ubiquitin-mediated degradation of a cell-cycle regulatory protein, such as p53, p27, myc, fos, MAT.alpha.2, or cyclins. The invention further relates to novel ubiquitin-conjugating enzymes, and uses related thereto.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: October 19, 1999
    Assignee: Mitotix, Inc.
    Inventors: Mark Rolfe, Maria Isabel Chiu, Guillaume Cottarel, Vivian Berlin, Veronique Damagnez, Giulio Draetta
  • Nucleic acid encoding a Candida cell cycle regulatory protein, TYP1 polypeptide
    Patent number: 5801015
    Abstract: The present invention relates to the discovery of novel cell cycle regulatory proteins from the human pathogen Candida.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: September 1, 1998
    Assignee: Mitotix, Inc.
    Inventors: Guillaume Cottarel, Veronique Damagnez, Giulio Draetta
  • Methods of identifying inhibitors of cdc25 phosphatase
    Patent number: 5443962
    Abstract: The present invention makes available assays and reagents for identifying anti-proliferative agents, such as mitotic and meiotic inhibitors, especially inhibitors of cdc25 phosphatase. The present assay provides a simple and rapid screening test which relies on scoring for positive cellular proliferation as indicative of anti-mitotic or anti-meiotic activity, and comprises contacting a candidate agent with a cell which has an impaired cell-cycle checkpoint and measuring the level of proliferation in the presence and absence of the agent. The checkpoint impairment is such that it either causes premature progression of the cell through at least a portion of a cell-cycle or inhibition of normal progression of the cell through at least a portion of a cell-cycle, but can be off-set by the action of an agent which inhibits at least one regulatory protein of the cell-cycle in a manner which counter-balances the effect of the impairment.
    Type: Grant
    Filed: June 4, 1993
    Date of Patent: August 22, 1995
    Assignee: Mitotix, Inc.
    Inventors: Giulio Draetta, Guillaume Cottarel, Veronique Damagnez